Caribou Biosciences reported long-term clinical data for vispa-cel, its allogeneic CAR-T cell therapy candidate, at the European Hematology Association (EHA) 2026 congress, showing durable responses in patients with second-line large B cell lymphoma (2L LBCL). The single-dose regimen produced an 82% overall response rate (ORR), a 67% complete response (CR) rate, and a median progression-free survival (mPFS) of 17.1 months — endpoints that the company says distinguish vispa-cel within an increasingly competitive cell therapy landscape.
Vispa-cel is an off-the-shelf, allogeneic CAR-T product derived from healthy donor T cells edited using Caribou's CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology. Unlike autologous approaches that require manufacturing from each patient's own cells, allogeneic platforms are engineered to reduce graft-versus-host disease risk while enabling scalable, ready-to-administer finished formulations. The 17.1-month mPFS figure is particularly notable given the historically poor prognosis for patients who relapse after or are ineligible for first-line chemoimmunotherapy, and it suggests the durability profile may hold up under continued follow-up.
The safety data continue to support outpatient administration, a clinically and commercially meaningful distinction. Outpatient delivery reduces facility burden and broadens the addressable treatment network to community oncology centers, which represent the majority of cancer care touchpoints in the United States. Caribou has indicated that this tolerability profile is central to its site-expansion strategy, with community center rollout identified as a near-term operational priority.
The global CAR-T therapy market was valued at approximately $5.8 billion in 2024 and is projected to expand at a compound annual growth rate exceeding 20.0% through the decade, driven by label expansions, earlier lines of therapy, and the logistical advantages that allogeneic platforms offer over autologous manufacturing. Payers and integrated delivery networks are increasingly receptive to off-the-shelf cell therapies that compress the vein-to-vein timeline and reduce the risk of patient deterioration during manufacturing wait periods.
For biopharma operators and investors tracking the cell therapy pipeline, the EHA data package reinforces vispa-cel's clinical differentiation story ahead of anticipated pivotal study readouts. Caribou has not yet announced a regulatory submission timeline, but the combination of a compelling efficacy signal, a manageable safety profile, and an outpatient-compatible administration model positions vispa-cel as one of the more closely watched allogeneic programs in hematologic oncology.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.